BioNTech (NASDAQ:BNTX) Shares Gap Down to $92.72

BioNTech SE (NASDAQ:BNTX - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $92.72, but opened at $90.09. BioNTech shares last traded at $92.49, with a volume of 481,363 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BNTX. The Goldman Sachs Group dropped their price target on shares of BioNTech from $113.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 28th. UBS Group dropped their target price on shares of BioNTech from $110.00 to $101.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 27th. BMO Capital Markets dropped their target price on shares of BioNTech from $127.00 to $123.00 and set an "outperform" rating on the stock in a research report on Thursday, March 21st. HC Wainwright reiterated a "buy" rating and set a $107.00 target price on shares of BioNTech in a research report on Wednesday, April 17th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $120.40.

BioNTech Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The company's fifty day simple moving average is $90.54 and its two-hundred day simple moving average is $95.99. The stock has a market cap of $22.19 billion, a price-to-earnings ratio of 22.66 and a beta of 0.25.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. On average, analysts forecast that BioNTech SE will post -1.74 earnings per share for the current year.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC raised its holdings in shares of BioNTech by 6.9% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company's stock valued at $186,000 after purchasing an additional 111 shares during the last quarter. Sectoral Asset Management Inc. raised its holdings in shares of BioNTech by 3.5% in the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company's stock valued at $374,000 after purchasing an additional 116 shares during the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in shares of BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company's stock valued at $492,000 after purchasing an additional 116 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of BioNTech by 3.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company's stock valued at $432,000 after purchasing an additional 148 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.